skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Ambrisentan for the treatment of pulmonary arterial hypertension

Review

(3081) Views  (1173) Full article downloads

Authors: Brian Casserly, James R Klinger

Published Date December 2008 Volume 2008:2 Pages 265 - 280
DOI: http://dx.doi.org/10.2147/DDDT.S3057

Brian Casserly1,3, James R Klinger2,3

1Division of Pulmonary Medicine, The Memorial Hospital of Rhode Island, Pawtucket, RI, USA; 2Division of Pulmonary Sleep and Critical Care Medicine, Rhode Island Hospital; 3Waren Alpert Medical School of Brown University, Providence, RI, USA

Abstract: Ambrisentan is an endothelin receptor antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH). Endothelin (ET) is a potent vasoconstrictor with mitogenic, hypertrophic and pro-inflammatory properties that is upregulated in pulmonary hypertensive diseases. The biologic effects of ET are mediated by 2 cell surface receptors termed ETA and ETB. ETA mediates the vasoconstrictor effect of ET on vascular smooth muscle, whereas ETB is expressed primarily on vascular endothelial cells where it induces nitric oxide synthesis and acts to clear ET from the circulation. Ambrisentan is the first ETA selective ERA approved for use in the US. Recently published clinical trials in patients with PAH demonstrate improvement in functional capacity and pulmonary hemodynamics similar to other ETA selective and non-selective ERAs. Its once daily dosing and lower incidence of serum aminotransferase elevation offer potential advantages over other ERAs, but further experience with this agent is needed to fully understand its long-term efficacy and safety. This review discusses the endothelin family of proteins and receptors and their role in the pathophysiology of pulmonary hypertensive diseases. It also examines the development process, safety profile and clinical trials that have resulted in ambrisentan being approved for treatment of PAH.

Keywords: ambrisentan, endothelin receptor antagonist, pulmonary hypertension, endothelin






 

Other articles by Dr James Klinger



Readers of this article also read:

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
Periosteoplasty for covering gingival recessions: Clinical results
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Pharmacologic agents for smoking cessation: A clinical review
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
Treatment for primary hypothyroidism: current approaches and future possibilities
Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University